FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891448835> ?p ?o ?g. }

• W2891448835 endingPage "11547" @default.
• W2891448835 startingPage "11547" @default.
• W2891448835 abstract "11547 Background: Inhibition of programmed-death 1 (PD1) by pembrolizumab (P) produced overall response rates (ORR) of 19% in advanced STS [SARC028]. Vascular endothelial growth factor (VEGF) suppresses the immune microenvironment and may contribute to checkpoint inhibitor resistance. Axitinib (Ax) is a pan-VEGFR inhibitor that prolongs progression-free survival (PFS) in advanced STS [Axi-STS], with striking antitumor activity in combination with P in renal cell carcinoma. We report toxicity, efficacy, and correlative endpoints of combination Ax/P for patients (pts) with advanced STS. Methods: NCT02301039 is an open-label Phase II trial of Ax/P in 30 pts with advanced or metastatic STS, requiring RECIST 1.1 progressing disease, adequate end-organ function and performance status. Pts received Ax 5 mg PO twice daily with concurrent P 200mg IV q21 days. Primary endpoint: 3-month PFS rate (PFS3mo); secondary endpoints: toxicity, ORR and clinical benefit rate (CBR) by RECIST 1.1, and overall survival. Tumor biopsies and peripheral blood samples were obtained for correlative studies of TIL and PBMC at baseline, 3 months on treatment, and at progression. Results: 33 pts received at least one dose of study drugs, with 30 pts evaluable for primary endpoint. Enrolled subtypes: ASPS (36%), UPS (15%), LMS (18%), other (30%). PFS3mo was 70.3% [95% CI 50.7-83.3], with median PFS of 5.4 months [95% CI 3.02-11.6]. Best ORR was 21.9% [95% CI 5.9-33.5]. PFS3mo in ASPS pts was 90.9% [95% CI 50.8-98.7], with best ORR of 45.5% [95% CI 18.1-75.4] and CBR of 72.7% [95% CI 39.3-92.7]. Ax/P was well-tolerated, with similar immune-related toxicity rates to prior studies. Correlative markers were analyzed by a penalized logistic regression model with bootstrapping to predict PFS3mo. Baseline high plasma angiogenic activity, circulating neutrophil:lymphocyte ratio < 4.1, low naïve fraction CD4+ TIL, and low PD1+CD8+ PBMC were associated with lack of progression (AUC 0.878 [95% CI 0.743-1, p = 0.0002]). Conclusions: Combination Ax/P is well-tolerated with promising activity in ASPS pts. Identified immune correlates associated with PFS should be validated in prospective immunotherapy trials. Clinical trial information: NCT02301039." @default.
• W2891448835 created "2018-09-27" @default.
• W2891448835 creator A5002711717 @default.
• W2891448835 creator A5004418792 @default.
• W2891448835 creator A5004799762 @default.
• W2891448835 creator A5024913801 @default.
• W2891448835 creator A5025985136 @default.
• W2891448835 creator A5031530983 @default.
• W2891448835 creator A5033315908 @default.
• W2891448835 creator A5037593731 @default.
• W2891448835 creator A5040686884 @default.
• W2891448835 creator A5043773782 @default.
• W2891448835 creator A5046981381 @default.
• W2891448835 creator A5054187824 @default.
• W2891448835 creator A5057832944 @default.
• W2891448835 creator A5090391845 @default.
• W2891448835 date "2018-05-20" @default.
• W2891448835 modified "2023-09-22" @default.
• W2891448835 title "A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS)." @default.
• W2891448835 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.11547" @default.
• W2891448835 hasPublicationYear "2018" @default.
• W2891448835 type Work @default.
• W2891448835 sameAs 2891448835 @default.
• W2891448835 citedByCount "7" @default.
• W2891448835 countsByYear W28914488352018 @default.
• W2891448835 countsByYear W28914488352020 @default.
• W2891448835 countsByYear W28914488352021 @default.
• W2891448835 countsByYear W28914488352022 @default.
• W2891448835 countsByYear W28914488352023 @default.
• W2891448835 crossrefType "journal-article" @default.
• W2891448835 hasAuthorship W2891448835A5002711717 @default.
• W2891448835 hasAuthorship W2891448835A5004418792 @default.
• W2891448835 hasAuthorship W2891448835A5004799762 @default.
• W2891448835 hasAuthorship W2891448835A5024913801 @default.
• W2891448835 hasAuthorship W2891448835A5025985136 @default.
• W2891448835 hasAuthorship W2891448835A5031530983 @default.
• W2891448835 hasAuthorship W2891448835A5033315908 @default.
• W2891448835 hasAuthorship W2891448835A5037593731 @default.
• W2891448835 hasAuthorship W2891448835A5040686884 @default.
• W2891448835 hasAuthorship W2891448835A5043773782 @default.
• W2891448835 hasAuthorship W2891448835A5046981381 @default.
• W2891448835 hasAuthorship W2891448835A5054187824 @default.
• W2891448835 hasAuthorship W2891448835A5057832944 @default.
• W2891448835 hasAuthorship W2891448835A5090391845 @default.
• W2891448835 hasConcept C121608353 @default.
• W2891448835 hasConcept C126322002 @default.
• W2891448835 hasConcept C142724271 @default.
• W2891448835 hasConcept C143998085 @default.
• W2891448835 hasConcept C203092338 @default.
• W2891448835 hasConcept C2776539811 @default.
• W2891448835 hasConcept C2776694085 @default.
• W2891448835 hasConcept C2777472916 @default.
• W2891448835 hasConcept C2777701055 @default.
• W2891448835 hasConcept C2778256501 @default.
• W2891448835 hasConcept C2778629024 @default.
• W2891448835 hasConcept C2779490328 @default.
• W2891448835 hasConcept C2779984678 @default.
• W2891448835 hasConcept C2780057760 @default.
• W2891448835 hasConcept C2780739268 @default.
• W2891448835 hasConcept C29730261 @default.
• W2891448835 hasConcept C31760486 @default.
• W2891448835 hasConcept C535046627 @default.
• W2891448835 hasConcept C71924100 @default.
• W2891448835 hasConcept C90924648 @default.
• W2891448835 hasConceptScore W2891448835C121608353 @default.
• W2891448835 hasConceptScore W2891448835C126322002 @default.
• W2891448835 hasConceptScore W2891448835C142724271 @default.
• W2891448835 hasConceptScore W2891448835C143998085 @default.
• W2891448835 hasConceptScore W2891448835C203092338 @default.
• W2891448835 hasConceptScore W2891448835C2776539811 @default.
• W2891448835 hasConceptScore W2891448835C2776694085 @default.
• W2891448835 hasConceptScore W2891448835C2777472916 @default.
• W2891448835 hasConceptScore W2891448835C2777701055 @default.
• W2891448835 hasConceptScore W2891448835C2778256501 @default.
• W2891448835 hasConceptScore W2891448835C2778629024 @default.
• W2891448835 hasConceptScore W2891448835C2779490328 @default.
• W2891448835 hasConceptScore W2891448835C2779984678 @default.
• W2891448835 hasConceptScore W2891448835C2780057760 @default.
• W2891448835 hasConceptScore W2891448835C2780739268 @default.
• W2891448835 hasConceptScore W2891448835C29730261 @default.
• W2891448835 hasConceptScore W2891448835C31760486 @default.
• W2891448835 hasConceptScore W2891448835C535046627 @default.
• W2891448835 hasConceptScore W2891448835C71924100 @default.
• W2891448835 hasConceptScore W2891448835C90924648 @default.
• W2891448835 hasIssue "15_suppl" @default.
• W2891448835 hasLocation W28914488351 @default.
• W2891448835 hasOpenAccess W2891448835 @default.
• W2891448835 hasPrimaryLocation W28914488351 @default.
• W2891448835 hasRelatedWork W2785838318 @default.
• W2891448835 hasRelatedWork W2891448835 @default.
• W2891448835 hasRelatedWork W2931109290 @default.
• W2891448835 hasRelatedWork W3135426710 @default.
• W2891448835 hasRelatedWork W3166072320 @default.
• W2891448835 hasRelatedWork W3177224496 @default.
• W2891448835 hasRelatedWork W4226256362 @default.
• W2891448835 hasRelatedWork W4361947625 @default.
• W2891448835 hasRelatedWork W4361954108 @default.
• W2891448835 hasRelatedWork W4379345918 @default.

• next